Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Severe combined immunodeficiency (SCID) mice are defective in their ability to rearrange their variable (V), diversity (D) and joining (J) genetic elements to generate functional immunoglobulin (Ig) and T-cell receptor (TCR) molecules; as a result, they lack mature B and T cells. These mice are highly sensitive to ionizing radiation, suggesting that the product of the scid gene plays a critical role in both V(D)J recombination and DNA double-strand break repair. Recent studies suggest that the SCID defect lies in the gene encoding the catalytic subunit of
DNA-dependent protein kinase
(
DNA-PK
; refs 6-8), a nuclear protein made up of the Ku 70 and Ku 86 subunits as well as the large catalytic subunit,
DNA-PKcs
. Other reports have implied that the SCID phenotype correlates with nonsense mutations at the extreme 3' end of
Prkdc
, the
DNA-PKcs
gene. The identity of the gene remains in doubt, however, because the consequences of genetic inactivation of
Prkdc
have not been determined. This study shows that complete inactivation of
Prkdc
in a novel insertional mouse mutant recapitulates the SCID phenotype and that
Prkdc
and scid are alleic. Significantly,
DNA-PKcs
null mice demonstrate complete penetrance of thymic lymphoblastic lymphomas, strongly suggesting that
Prkdc
functions in mice as a T-cell
tumour suppressor
and, by virtue of its association with DNA repair and recombination, belongs to the 'caretaker' class of tumour-suppressor genes that includes ATM, BRCA1 and BRCA2 (ref. 15).
...
PMID:DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. 939 56
The
tumour suppressor
p53 becomes activated as a transcription factor in response to DNA damage, but the mechanism for this activation is unclear. A good candidate for an upstream activator of p53 is the
DNA-dependent protein kinase
(
DNA-PK
) that depends on the presence of DNA breaks for its activity. Here we investigate the link between DNA damage and the activation of
DNA-PK
and of p53. To determine whether
DNA-PK
is an upstream mediator of the p53 DNA-damage response, we analysed a severe combined-immunodeficiency (SCID) mouse cell line, SCGR11, and the human glioma cell line M059J . Both cell lines lack any detectable
DNA-PK
activity. We find that p53 is incapable of binding to DNA in the absence of
DNA-PK
, that
DNA-PK
is necessary but not sufficient for activation of p53 sequence-specific DNA binding, and that this activation occurs in response to DNA damage. Our results establish
DNA-PK
as a link between DNA damage and p53 activation, and reveal the existence of a mammalian DNA-damage-response pathway.
...
PMID:DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. 971 37
The
tumour suppressor
gene product, p53, is involved in mediating cellular responses to DNA damage including growth arrest and/or apoptosis. The mechanism by which p53 protein senses the presence of damaged DNA is not understood. The possibility that p53 may be post-translationally modified by enzymes that are activated in response to DNA damage including
DNA-dependent protein kinase
(
DNA-PK
), poly(ADP-ribose) polymerase and stress activated protein kinase has received considerable attention. Recent studies have indicated that
DNA-PK
is not required for the transactivation or apoptosis-promoting activities of p53 protein. However, the possibility that other functions of p53 may be dependent on phosphorylation by
DNA-PK
has not been explored. Here we describe a series of experiments that compares the expression, function and phosphorylation status of p53 protein in normal and
DNA-PK
-deficient scid cells. While several novel p53 phosphoforms are generated in response to DNA damage in normal cells, the same phosphoforms are observed in scid cells.
...
PMID:Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells. 1010 21
Levels of the
tumour suppressor
protein p53 are increased in response to a variety of DNA damaging agents. DNA damage-induced phosphorylation of p53 occurs at serine-15 in vivo. Phosphorylation of p53 at serine-15 leads to a stabilization of the polypeptide by inhibiting its interaction with Mdm2, a protein that targets p53 for ubiquitin-dependent degradation. However, the mechanisms by which DNA damage is signalled to p53 remain unclear. Here, we report the identification of a novel DNA-activated protein kinase that phosphorylates p53 on serine-15. Fractionation of HeLa nuclear extracts and biochemical analyses indicate that this kinase is distinct from the
DNA-dependent protein kinase
(
DNA-PK
) and corresponds to the human cell cycle checkpoint protein ATR. Immunoprecipitation studies of recombinant ATR reveal that catalytic activity of this polypeptide is required for DNA-stimulated phosphorylation of p53 on serine-15. These data suggest that ATR may function upstream of p53 in a signal transduction cascade initiated upon DNA damage and provide a biochemical assay system for ATR activity.
...
PMID:The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. 1043 22
The serine/threonine protein kinase LKB1 functions as a
tumour suppressor
, and mutations in this enzyme lead to the inherited Peutz-Jeghers cancer syndrome. We previously found that LKB1 was phosphorylated at Thr-366 in vivo, a residue conserved in mammalian, Xenopus and Drosophila LKB1, located on a C-terminal non-catalytic moiety of the enzyme. Mutation of Thr-366 to Ala or Asp partially inhibited the ability of LKB1 to suppress growth of G361 melanoma cells, but did not affect LKB1 activity in vitro or LKB1 localization in vivo. As a first step in exploring the role of this phosphorylation further, we have generated a phosphospecific antibody specifically recognizing LKB1 phosphorylated at Thr-366 and demonstrate that exposure of cells to ionizing radiation (IR) induced a marked phosphorylation of LKB1 at Thr-366 in the nucleus. Thr-366 lies in an optimal phosphorylation motif for the phosphoinositide 3-kinase-like kinases
DNA-dependent protein kinase
(
DNA-PK
), ataxia telangiectasia mutated kinase (ATM) and ataxia telangiectasia-related kinase (ATR), which function as sensors for DNA damage in cells and mediate cellular responses to DNA damage. We demonstrate that both
DNA-PK
and ATM efficiently phosphorylate LKB1 at Thr-366 in vitro and provide evidence that ATM mediates this phosphorylation in vivo. This is based on the finding that LKB1 is not phosphorylated in a cell line lacking ATM in response to IR, and that agents which induce cellular responses via ATR in preference to ATM poorly induce phosphorylation of LKB1 at Thr-366. These observations provide the first link between ATM and LKB1 and suggest that ATM could regulate LKB1.
...
PMID:Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. 1223 50
Although little is understood of the underlying mechanisms, there are tissue-specific responses to tumourigenic and therapeutic agents and these responses are influenced by genetic factors. Ionizing radiation is an important tumourigenic and therapeutic agent for which there is substantial evidence for such tissue-dependent and genotype-dependent responses. Because the p53
tumour suppressor
protein is a major determinant of cellular responses to radiation, the present study has investigated whether modification of the p53 pathway contributes to tissue-dependent and genotype-dependent responses using inbred strains of mice. Comparison of responses in haemopoietic and epithelial cells in irradiated C57BL/6 and DBA/2 mice revealed significant differences in p53 and apoptotic responses in different cell types and in different cells of the same type, reflecting the complexity of damage responses operating in the whole organism. The data suggest that p53-mediated up-regulation of Bax is a major determinant of apoptosis in the spleen, but not in the intestine, whereas p53-mediated induction of p21(waf1) plays an anti-apoptotic role in the spleen, but not in the intestine. It is also shown that p53 stabilization and differential transactivational activities towards Bax or p21(waf1) are influenced by genetic factors that act in a tissue-specific manner. Analysis of ATM, a potential mediator of differential p53 activation, indicates that this key regulator of radiation responses is preferentially induced in epithelial cells, but is unlikely to account for genetic modification of p53 or apoptotic responses in the mouse strains studied. Polymorphisms in the p53 or
DNA-PKcs
genes are also unlikely to account for the genetic modifications that are reported here. There are numerous further potential modifiers of the p53 pathway, but analysis of backcross and inter-cross mice demonstrates that genes responsible for the complex modification of these in vivo responses can be identified by linkage analysis. This approach has the potential to reveal new or unexpected interactions involving the p53 pathway that determine both short-term and long-term effects of radiation exposure and the basis of tissue-specific responses and tumour susceptibility.
...
PMID:Tissue-specific p53 responses to ionizing radiation and their genetic modification: the key to tissue-specific tumour susceptibility? 1459 49
DNA repair pathways enable tumour cells to survive DNA damage induced by external agents such as therapeutic treatments. Signalling cascades involved in these pathways comprise the
DNA-dependent protein kinase
(
DNA-PK
), Ataxia-telangiectasia mutated (ATM), ATM and Rad3 related (ATR) and checkpoint kinases I and 2 (Chk1/Chk2), among others. ATM and ATR phosphorylate, respectively, Chk2 and Chk1, leading to activation of checkpoints. Chk2 acts as a signal distributor, dispersing checkpoint signal to downstream targets such as p53, Cdc25A, Cdc25C, BRCA1 and E2F1. A role of Chk2 as a candidate
tumour suppressor
has been suggested based on both mouse genetics and somatic tumour studies. We will discuss here the possible role of this kinase in human carcinogenesis and the possibility to use it as a target to increment DNA damage in cancer cells in response to DNA-damaging therapies.
...
PMID:Role of CHK2 in cancer development. 1879 70
p53 is required for DNA damage-induced apoptosis, which is central to its function as a
tumour suppressor
. Here, we show that the apoptotic defect of p53-deficient cells is nearly completely rescued by inactivation of any of the three subunits of the DNA repair holoenzyme
DNA-dependent protein kinase
(
DNA-PK
). Intestinal crypt cells from p53 nullizygous mice were resistant to radiation-induced apoptosis, whereas apoptosis in
DNA-PK
(cs)/p53, Ku80/p53 and Ku70/p53 double-null mice was quantitatively equivalent to that seen in wild-type mice. This p53-independent apoptotic response was specific to the loss of
DNA-PK
, as it was not seen in ligase IV (Lig4)/p53 or ataxia telangiectasia mutated (Atm)/p53 double-null mice. Furthermore, it was associated with an increase in phospho-checkpoint kinase 2 (CHK2), and cleaved caspases 3 and 9, the latter indicating engagement of the intrinsic apoptotic pathway. This shows that there are two separate, but equally effective, apoptotic responses to DNA damage: one is p53 dependent and the other, engaged in the absence of
DNA-PK
, does not require p53.
...
PMID:DNA-PK suppresses a p53-independent apoptotic response to DNA damage. 1905 78
The
DNA-dependent protein kinase
(
DNA-PK
), which comprises the KU heterodimer and a catalytic subunit (
DNA-PKcs
), is a classical non-homologous end-joining (cNHEJ) factor
1
. KU binds to DNA ends, initiates cNHEJ, and recruits and activates
DNA-PKcs
. KU also binds to RNA, but the relevance of this interaction in mammals is unclear. Here we use mouse models to show that
DNA-PK
has an unexpected role in the biogenesis of ribosomal RNA (rRNA) and in haematopoiesis. The expression of kinase-dead
DNA-PKcs
abrogates cNHEJ
2
. However, most mice that both expressed kinase-dead
DNA-PKcs
and lacked the
tumour suppressor
TP53 developed myeloid disease, whereas all other previously characterized mice deficient in both cNHEJ and TP53 expression succumbed to pro-B cell lymphoma
3
.
DNA-PK
autophosphorylates
DNA-PKcs
, which is its best characterized substrate. Blocking the phosphorylation of
DNA-PKcs
at the T2609 cluster, but not the S2056 cluster, led to KU-dependent defects in 18S rRNA processing, compromised global protein synthesis in haematopoietic cells and caused bone marrow failure in mice. KU drives the assembly of
DNA-PKcs
on a wide range of cellular RNAs, including the U3 small nucleolar RNA, which is essential for processing of 18S rRNA
4
. U3 activates purified
DNA-PK
and triggers phosphorylation of
DNA-PKcs
at T2609.
DNA-PK
, but not other cNHEJ factors, resides in nucleoli in an rRNA-dependent manner and is co-purified with the small subunit processome. Together our data show that
DNA-PK
has RNA-dependent, cNHEJ-independent functions during ribosome biogenesis that require the kinase activity of
DNA-PKcs
and its phosphorylation at the T2609 cluster.
...
PMID:DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis. 3215